Rewind Therapeutics

Rewind Therapeutics is a Belgium-based biotechnology company that researches and develops remyelinating therapies for the treatment of multiple sclerosis.

Business Model:

Revenue: $3.1M

Employees: 11-50

Detailed Rewind Therapeutics Information

Geographic Data

Rewind Therapeutics headquarters map

Address: Gaston Geenslaan 2

City: Leuven

State: flemish brabant

Zip: 3001

Country: BE

Financial Info

Stage:

series b

Raised Last:

$0

Raised Total:

$22M

Metrics

2,626,402Website Global Rank

5,537Website Monthly Traffic

Twitter Followers

Description

Rewind Therapeutics is a Belgium-based biotechnology company that researches and develops remyelinating therapies for the treatment of multiple sclerosis.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
8/2019 Grant 1 $3.2M Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
1/2023 Series A -
7/2019 Grant $3.2M
1/2023 Series A - Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Sunstone Life Science Ventures
Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Sunstone Life Science Ventures
Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Sunstone Life Science Ventures
Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Sunstone Life Science Ventures
1/2023 Series B 6 - Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Sunstone Life Science Ventures
Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Sunstone Life Science Ventures
1/2018 Series A 5 $18.3M Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
1/2018 Series A $18.3M Boehringer Ingelheim Venture Fund
Merck Ventures BV
Participatiemaatschappij Vlaanderen
KU Leuven's Centre for Drug Design and Discovery (CD3)
1/2023 Series A - Boehringer Ingelheim Venture Fund
M. Ventures
PMV
CD3/ KU
Sunstone Life Science Ventures
Boehringer Ingelheim Venture Fund
M. Ventures
PMV
CD3/ KU
Sunstone Life Science Ventures
1/2023 Series B 6 - Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Sunstone Life Science Ventures
Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Sunstone Life Science Ventures
8/2019 Grant 1 $3.2M Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
1/2018 Series A 5 $18.3M Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Boehringer Ingelheim Venture Fund
Centre for Drug Design &a; Discovery (CD3)
Gemma Frisius Fund
M Ventures
PMV
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research